Sorafenib Accord

Authorised

This medicine is authorised for use in the European Union

sorafenib

Overview

Sorafenib Accord is a cancer medicine used to treat patients who have the following diseases:

• hepatocellular carcinoma (a type of liver cancer);
• advanced renal cell carcinoma (a type of kidney cancer) when cancer treatment with interferon alpha or interleukin-2 has failed or cannot be used;

Sorafenib Accord contains the active substance sorafenib.

Sorafenib Accord is a ‘generic medicine’. This means that Sorafenib Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Nexavar. For more information on generic medicines, see the question-and-answer document here.

How is Sorafenib Accord used?

Sorafenib Accord can only be obtained with a prescription. Treatment with Sorafenib Accord should be supervised by doctors who have experience in using cancer treatments.

Sorafenib Accord is given as two tablets twice a day, without food or with a meal that has a low or moderate fat content. Treatment should continue as long as the patient continues to benefit from it without too many side effects. To manage side effects, treatment may be temporarily interrupted or the dose may be reduced.

For more information about using Sorafenib Accord, see the package leaflet or contact your doctor or pharmacist.

How does Sorafenib Accord work?

The active substance in Sorafenib Accord, sorafenib, is a protein kinase inhibitor. This means that it blocks some specific enzymes known as protein kinases that are involved in the growth and spread of cancer cells, as well as in the development of new blood vessels supplying the tumours. By blocking these enzymes, Sorafenib Accord can reduce the growth of cancer cells and cut off the blood supply that keeps them growing.

How has Sorafenib Accord been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Nexavar, and do not need to be repeated for Sorafenib Accord.

As for every medicine, the company provided studies on the quality of Sorafenib Accord. The company also carried out a study that showed that it is ‘bioequivalent’ to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

What are the benefits and risks of Sorafenib Accord?

Because Sorafenib Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Why is Sorafenib Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sorafenib Accord has been shown to have comparable quality and to be bioequivalent to Nexavar. Therefore, the Agency’s view was that, as for Nexavar, the benefits of Sorafenib Accord outweigh the identified risks and it can be authorised for use in the EU.

What measures are being taken to ensure the safe and effective use of Sorafenib Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sorafenib Accord have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sorafenib Accord are continuously monitored. Suspected side effects reported with Sorafenib Accord are carefully evaluated and any necessary action taken to protect patients.

Other information about Sorafenib Accord

Sorafenib Accord received a marketing authorisation valid throughout the EU on 9 November 2022.

Sorafenib Accord : EPAR - Medicine Overview

Reference Number: EMA/781233/2022

Sorafenib Accord : EPAR - Risk management plan summary

Product information

Sorafenib Accord : EPAR - Product Information

Sorafenib Accord : EPAR - All authorised presentations

Product details

• Name of medicine:
  Sorafenib Accord
• Active substance:
  Sorafenib tosilate
• International non-proprietary name (INN) or common name:
  sorafenib
• Therapeutic area (MeSH):
  • Carcinoma, Hepatocellular
  • Carcinoma, Renal Cell
• Anatomical therapeutic chemical (ATC) code:
  L01EX02

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Hepatocellular carcinoma
Sorafenib Accord is indicated for the treatment of hepatocellular carcinoma (see section 5.1).

Renal cell carcinoma
Sorafenib Accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Authorisation details

• EMA product number:
  EMEA/H/C/005921
• Generic:

  This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

• Marketing authorisation holder:
  Accord Healthcare S.L.U.

  Edificio Este Planta 6a; World Trade Center; Moll De Barcelona S/n; 08039 Barcelona; SPAIN

• Opinion adopted:
  15/09/2022
• Marketing authorisation issued:
  09/11/2022
• Revision:
  1

Assessment history

Changes since initial authorisation of medicine

Sorafenib Accord : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Sorafenib Accord : EPAR - Public assessment report

AdoptedReference Number: EMA/834802/2022

CHMP summary of positive opinion for Sorafenib Accord

AdoptedReference Number: EMA/CHMP/758392/2022